Loading…
Reported covered position: Head of Government Affairs
How to read the money
Income and expense are whole-filing amounts associated with this lobbyist, not personal compensation or an allocated share.
No topic inference: each bill number appears in source LDA issue text assigned to this lobbyist.
Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2018
Client: AVANIR PHARMACEUTICALS · Firm: AVANIR PHARMACEUTICALS
Alzheimer's research funding in the FY18 House and Senate Labor, HHS and Education Appropriations bills HR 3358 and S. 1771.
Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2018
Client: AVANIR PHARMACEUTICALS · Firm: AVANIR PHARMACEUTICALS
Specific issues are shown only where the LDA source assigned them to this lobbyist. Targets apply to the associated filing.
AVANIR PHARMACEUTICALS via AVANIR PHARMACEUTICALS
2017 · fourth_quarter · 4T
Alzheimer's research funding in the FY18 House and Senate Labor, HHS and Education Appropriations bills HR 3358 and S. 1771.
Long term care regulations; out of pocket costs.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
Source: Senate LDA
Alzheimer's research funding in the FY18 House and Senate Labor, HHS and Education Appropriations bills HR 3358 and S. 1771.
Southwest Border Regional Commission Reauthorization Act of 2018
Client: AVANIR PHARMACEUTICALS · Firm: AVANIR PHARMACEUTICALS
Alzheimer's research funding in the FY17 House and Senate Labor, HHS and Education Appropriations bill-H.R. 5325 and S. 2955.
Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2018
Client: AVANIR PHARMACEUTICALS · Firm: AVANIR PHARMACEUTICALS
Alzheimer's research funding in the FY18 House and Senate Labor, HHS and Education Appropriations bills HR 3358 and S. 1771.
Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2018
Client: AVANIR PHARMACEUTICALS · Firm: AVANIR PHARMACEUTICALS
Alzheimer's research funding in the FY18 House and Senate Labor, HHS and Education Appropriations bills HR 3358 and S. 1771.
Alzheimer's research funding in the FY17 House and Senate Labor, HHS and Education Appropriations bill-H.R. 5325 and S. 2955.
2017 · third_quarter · Q3
Long term care regulations; out of pocket costs.
Alzheimer's research funding in the FY18 House and Senate Labor, HHS and Education Appropriations bills HR 3358 and S. 1771.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
AVANIR PHARMACEUTICALS via AVANIR PHARMACEUTICALS
2017 · second_quarter · Q2
Alzheimer's research funding in the FY18 House and Senate Labor, HHS and Education Appropriations bills.
Long term care regulations; out of pocket costs.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
AVANIR PHARMACEUTICALS via AVANIR PHARMACEUTICALS
2017 · first_quarter · Q1
Long term care regulations; out of pocket costs.
Alzheimer's research funding in the FY17 House and Senate Labor, HHS and Education Appropriations bill-H.R. 5325 and S. 2955.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
AVANIR PHARMACEUTICALS via AVANIR PHARMACEUTICALS
2016 · fourth_quarter · Q4
Drug pricing
21st Century Cures, Specialty Tier Price Cap Legislation, Health Care Quality Measures, Out of Pocket Costs
Brain injury funding in the FY17 Labor, HHS, Education Appropriations Bills
Filing targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
AVANIR PHARMACEUTICALS via AVANIR PHARMACEUTICALS
2016 · third_quarter · Q3
Brain injury funding in the FY17 Labor, HHS, Education Appropriations Bills
21st Century Cures, Specialty Tier Price Cap Legislation, Health Care Quality Measures
Drug pricing
Filing targets: Agency for Healthcare Research & Quality (AHRQ), Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
AVANIR PHARMACEUTICALS via AVANIR PHARMACEUTICALS
2016 · second_quarter · 2A
21st Century Cures, Specialty Tier Price Cap Legislation, Health Care Quality Measures
Brain injury funding in the FY17 Labor, HHS, Education Appropriations Bills
Drug pricing
Filing targets: Agency for Healthcare Research & Quality (AHRQ), Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
AVANIR PHARMACEUTICALS via AVANIR PHARMACEUTICALS
2016 · second_quarter · Q2
Brain injury funding in the FY17 Labor, HHS, Education Appropriations Bills
Drug pricing
21st Century Cures, Specialty Tier Price Cap Legislation, Health Care Quality Measures
Filing targets: Agency for Healthcare Research & Quality (AHRQ), Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
AVANIR PHARMACEUTICALS via AVANIR PHARMACEUTICALS
2016 · first_quarter · Q1
21st Century Cures, Specialty Tier Price Cap Legislation, Health Care Quality Measures
Brain injury funding in the FY17 Labor, HHS, Education Appropriations Bills
Drug pricing
Filing targets: Agency for Healthcare Research & Quality (AHRQ), Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
AVANIR PHARMACEUTICALS via AVANIR PHARMACEUTICALS
2015 · third_quarter · 3A
SGR Repeal, 21st Century Cures, Specialty Tier Price Cap Legislation, Patent Reform, Health Care Quality Measures
Filing targets: Agency for Healthcare Research & Quality (AHRQ), Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
AVANIR PHARMACEUTICALS via AVANIR PHARMACEUTICALS
2015 · fourth_quarter · 4A
SGR Repeal, 21st Century Cures, Specialty Tier Price Cap Legislation, Patent Reform, Health Care Quality Measures
Filing targets: Agency for Healthcare Research & Quality (AHRQ), Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
AVANIR PHARMACEUTICALS via AVANIR PHARMACEUTICALS
2015 · fourth_quarter · Q4
SGR Repeal, 21st Century Cures, Specialty Tier Price Cap Legislation, Patent Reform, Health Care Quality Measures
Filing targets: Agency for Healthcare Research & Quality (AHRQ), Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
AVANIR PHARMACEUTICALS via AVANIR PHARMACEUTICALS
2015 · third_quarter · Q3
SGR Repeal, 21st Century Cures, Specialty Tier Price Cap Legislation, Patent Reform, Health Care Quality Measures
Filing targets: Agency for Healthcare Research & Quality (AHRQ), Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
AVANIR PHARMACEUTICALS via AVANIR PHARMACEUTICALS
2015 · second_quarter · Q2
SGR Repeal, 21st Century Cures, Specialty Tier Price Cap Legislation, Patent Reform, Health Care Quality Measures
Filing targets: Agency for Healthcare Research & Quality (AHRQ), Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
AVANIR PHARMACEUTICALS via AVANIR PHARMACEUTICALS
2015 · first_quarter · Q1
SGR Repeal, 21st Century Cures, Specialty Tier Price Cap Legislation, Patent Reform, Health Care Quality Measures
Filing targets: Agency for Healthcare Research & Quality (AHRQ), Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
AVANIR PHARMACEUTICALS via AVANIR PHARMACEUTICALS
2014 · fourth_quarter · Q4
21st Century Cures, Post-Acute Care Reform
Filing targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
AVANIR PHARMACEUTICALS via AVANIR PHARMACEUTICALS
2014 · fourth_quarter · RR
Pharmaceutical Research and Development, Post-Acute Care Reform, Central Nervous System Disorders, Patent Reform, FDA Reform, FDA Approval Pathways, Medicare/Medicaid
Pharmaceutical Research and Development, Post-Acute Care Reform, Central Nervous System Disorders, Patent Reform, FDA Reform, FDA Approval Pathways, Medicare/Medicaid